Trial Profile

EVOLVD: Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 26 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evolocumab (Primary)
Indications Hypercholesterolaemia
Focus Pharmacodynamics
Acronyms EVOLVD

Most Recent Events

30 Oct 2023 Status changed from active, no longer recruiting to completed.
26 Aug 2023 According to an Amgen media release, data this study of olpasiran, presented in a late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam.
20 May 2022 Planned End Date changed from 1 Jan 2022 to 20 May 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com